SenesTech Receives Nasdaq Minimum Bid Price Notification and Highlights Record Third Quarter Revenue
SenesTech, Inc. (SNES) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 SenesTech Receives Nasdaq Minimum Bid Price Notification and Highlights Record Third Quarter Revenue SURPRISE, Ariz., Oct. 22, 2026 — SenesTech, Inc. (NASDAQ: SNES), the leader in rodent birth control and sustainable rodent population management, today announced that
- Exchange
- Nasdaq Capital Market
- Kind
- deficiency
- Rule
- Nasdaq Listing Rule 5550(a)(2)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The disclosure creates immediate compliance uncertainty, but the record Q3 revenue suggests operational momentum that could support a price recovery.
Market read
Micro‑cap investors will monitor the compliance deadline and any financing actions; the revenue beat may attract speculative buying.
What to watch
Potential upcoming financing or strategic partnership could mitigate the compliance risk.
Background
SenesTech, a Nasdaq‑listed micro‑cap specializing in rodent birth‑control solutions, received a formal notice that its share price fell below the $1 minimum for 30 days, triggering a 180‑day compliance window.
Ticker impact
SenesTech disclosed a Nasdaq minimum bid price notification and reported record Q3 revenue of $1.1 million, indicating compliance risk and a potential upside if the price recovers.
likely pressure as investors price in the compliance risk, with upside potential if the company regains $1 compliance.
Nasdaq notifications historically trigger short‑term sell‑offs for low‑priced stocks, while a 40% sequential revenue jump provides a catalyst for a rebound if compliance is achieved.
Market effects
Highlights compliance risk for other micro‑cap biotech/pest‑control firms listed on Nasdaq Capital Market.
Limited to U.S. over‑the‑counter micro‑cap segment; no broader regional effect.
Minimal global impact; primarily relevant to investors in U.S. micro‑caps.
Counterpoint
The compliance notice may be over‑priced; the revenue surge could drive a short‑cover rally.
Key entities
- ExecutiveMichael Edell
President and CEO of SenesTech, commented on the compliance notice and revenue growth.
- InvestorGlenbrook Capital Management
Long‑term holder with 38% ownership, offered to cooperate on financial measures.
